52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
EMA Issues Advice On Regeneron's Antibody Cocktail For Certain COVID-19 Patients
EMA Issues Advice On Use Of REGN-COV2 Antibody Combination
Regeneron Pharmaceuticals Says Independent Data Monitoring Committee Finds Clear Efficacy For Regen-Cov In Phase 3 Covid-19 Outpatient Outcomes Trial
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Biotechnology & Drugs
777 Old Saw Mill River Rd
P. Roy Vagelos
Chairman of the Board, Director
Leonard S. Schleifer
President, Chief Executive Officer, Director
George D. Yancopoulos
President, Chief Scientific Officer, Director
Robert E. Landry
Chief Financial Officer, Executive Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Europe's medicines regulator said on Friday an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.
Europe's medicines regulator said on Friday that an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COVID-19 patients who do not require oxygen support and are at high risk of progressing to severe illness.
Regeneron Pharmaceuticals said on Thursday that an independent panel found the company's COVID-19 antibody cocktail to have "clear clinical efficacy" in reducing the rates of hospitalization and deaths in patients.
The Czech Republic, hard-hit by the COVID-19 pandemic, has ordered 12,000 doses of an antibody treatment made by Regeneron ahead of its registration by European authorities and will start receiving it in March, Prime Minister Andrej Babis said on Saturday.
A federal appeals court has rejected a bid by Amgen Inc to revive patents on its cholesterol drug Repatha after they were ruled invalid by a district court, a victory for Regeneron Pharmaceuticals Inc and Sanofi SA, which sell a rival drug.
The Czech Health Ministry will recommend the use of COVID-19 therapies that contain casirivimab/imdevimab and bamlavinimab antibodies ahead of standard approval, the ministry said on Monday.
Italy's medicines regulator AIFA has given the green light for emergency use of COVID-19 antibody therapies developed by U.S drugmakers Eli Lilly and Regeneron, it said on Friday.
Regeneron Pharmaceuticals Inc's quarterly profit surged past estimates on Friday, benefiting from a recovery in demand for its flagship eye drug and a jump in sales of its eczema drug, sending the drugmaker's shares up 3% before the bell.
Regeneron Pharmaceuticals Inc on Friday reported a 45% rise in quarterly profit, benefiting from a recovery in demand for its flagship eye drug, Eylea, which took a hit last year due to the pandemic.
Europe's drugs regulator said on Thursday it was reviewing data on COVID-19 antibody therapies developed by U.S. drugmakers Eli Lilly and Regeneron for use in some patients.
Europe's drugs regulator said on Thursday it will begin reviewing data on U.S. drugmakers Eli Lilly and Regeneron's combination therapies of antibody-based treatments for use in COVID-19 patients.
Europe's health regulator on Monday said it had started a real-time review of Regeneron Pharmaceuticals Inc's antibody therapy for the treatment and prevention of COVID-19.
Laboratory testing found that Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail can combat a coronavirus variant first found in South Africa, but a similar drug from Eli Lilly and Co is inactive against it, according to a study released on Tuesday.
COVID-19 antibody drugs developed by Eli Lilly and Co and Regeneron may be weaker against a new coronavirus variant found in South Africa, according to a study released on Tuesday based on laboratory tests.
Regeneron Pharmaceuticals Inc said on Tuesday its antibody cocktail was found effective in preventing COVID-19 in people exposed to those infected with the new coronavirus in an ongoing late stage trial.
Regeneron Pharmaceuticals Inc said on Tuesday its antibody cocktail was effective in preventing COVID-19 in people exposed to those infected with the new coronavirus, based on interim results from a late-stage study.
The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals' COVID-19 antibody cocktail for about $2.63 billion, bringing the total supply of the treatment to more than 1.5 million doses.
The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail to be used in non-hospitalized COVID-19 patients, the drugmaker said on Tuesday.
Regeneron Pharmaceuticals Inc's dual antibody therapy for COVID-19 will likely be effective against new variants of the coronavirus identified so far, the drugmaker's chief executive officer said on Monday.
* REGENERON EXECUTIVE SAYS ITS ANTIBODY COCKTAIL THERAPY AGAINST COVID-19 WILL LIKELY HELP AGAINST VARIANTS OF THE VIRUS - J.P.MORGAN CONF
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.